BACKGROUND: Epidermal growth factor receptor (EGFR) and c-erbB-2 are 2 of the 4 members of the erbB receptor family that play a role in signaling by forming heterodimers between family members. METHODS: The immunohistochemical expression of EGFR and c-erbB-2 was determined on 670 women who underwent operation for primary breast cancer. RESULTS: According to the combination of EGFR and c-erbB-2, 670 patients were classified into 4 groups: EGFR(-)/c-erbB-2(-) (417 patients); EGFR(+)/c-erbB-2(-) (136 patients); EGFR(-)/c-erbB-2(+) (72 patients); and EGFR(+)/c-erbB-2(+) (45 patients). Univariate analyses on disease-free and overall survival showed a significant difference among these 4 groups, whereas the difference between patients with positive and negative expression of EGFR was not statistically significant in patients with positive expression of c-erbB-2. A multivariate analysis indicated the combination of EGFR and c-erbB-2 to be an independently significant prognostic factor for disease-free and overall survival. CONCLUSIONS: Breast cancer with both a positive EGFR and c-erbB-2 expression had the worst prognosis, whereas the prognostic value of c-erbB-2 was stronger than that of EGFR in breast cancer.
BACKGROUND:Epidermal growth factor receptor (EGFR) and c-erbB-2 are 2 of the 4 members of the erbB receptor family that play a role in signaling by forming heterodimers between family members. METHODS: The immunohistochemical expression of EGFR and c-erbB-2 was determined on 670 women who underwent operation for primary breast cancer. RESULTS: According to the combination of EGFR and c-erbB-2, 670 patients were classified into 4 groups: EGFR(-)/c-erbB-2(-) (417 patients); EGFR(+)/c-erbB-2(-) (136 patients); EGFR(-)/c-erbB-2(+) (72 patients); and EGFR(+)/c-erbB-2(+) (45 patients). Univariate analyses on disease-free and overall survival showed a significant difference among these 4 groups, whereas the difference between patients with positive and negative expression of EGFR was not statistically significant in patients with positive expression of c-erbB-2. A multivariate analysis indicated the combination of EGFR and c-erbB-2 to be an independently significant prognostic factor for disease-free and overall survival. CONCLUSIONS:Breast cancer with both a positive EGFR and c-erbB-2 expression had the worst prognosis, whereas the prognostic value of c-erbB-2 was stronger than that of EGFR in breast cancer.
Authors: Mu-min Shao; Jun Liu; Joaquim S Vong; Yun Niu; Barbara Germin; Ping Tang; Anthony W H Chan; Philip C W Lui; Bonita K B Law; Puay-Hoon Tan; Gary M Tse Journal: Med Mol Morphol Date: 2011-03 Impact factor: 2.309
Authors: Norma O'Donovan; Annette T Byrne; Aisling E O'Connor; Sharon McGee; William M Gallagher; John Crown Journal: Invest New Drugs Date: 2010-03-16 Impact factor: 3.850
Authors: John Farley; Sartoru Fuchiuji; Kathleen M Darcy; Chunqiao Tian; William J Hoskins; William P McGuire; Parviz Hanjani; David Warshal; Benjamin E Greer; Jerome Belinson; Michael J Birrer Journal: Gynecol Oncol Date: 2009-03-09 Impact factor: 5.482
Authors: Dana M Brantley-Sieders; Guanglei Zhuang; Donna Hicks; Wei Bin Fang; Yoonha Hwang; Justin M M Cates; Karen Coffman; Dowdy Jackson; Elizabeth Bruckheimer; Rebecca S Muraoka-Cook; Jin Chen Journal: J Clin Invest Date: 2008-01 Impact factor: 14.808